NovaBridge Biosciences - NBP
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Chief Bus. Development Officer | S | D | 107,978.0 | 0.74 | 79,903.72 | 266,467.0 | View | |
| Sep 08, 2026 | Chief Bus. Development Officer | M | D | 45,320.0 | 0.0 | 0.0 | 135,960.0 | View | |
| Sep 08, 2026 | Chief Bus. Development Officer | M | D | 102,233.0 | 0.0 | 0.0 | 306,700.0 | View | |
| Sep 08, 2026 | Chief Bus. Development Officer | M | A | 104,236.0 | — | — | 374,445.0 | View | |
| Sep 08, 2026 | Chief Bus. Development Officer | M | A | 235,136.0 | — | — | 270,209.0 | View | |
| Sep 01, 2026 | EVP, Clinical Development | M | D | 4,079.0 | 0.0 | 0.0 | 28,558.0 | View | |
| Sep 01, 2026 | EVP, Clinical Development | S | D | 3,282.0 | 0.79 | 2,592.78 | 304,201.0 | View | |
| Sep 01, 2026 | EVP, Clinical Development | M | A | 9,382.0 | — | — | 307,483.0 | View | |
| Aug 25, 2026 | — | M | D | 7,486.0 | 0.0 | 0.0 | 14,974.0 | View | |
| Aug 25, 2026 | — | M | A | 17,218.0 | — | — | 17,218.0 | View | |
| Jul 10, 2026 | Chief Commercial Officer | A | A | 949,050.0 | 0.0 | 0.0 | 949,050.0 | View | |
| Jul 10, 2026 | General Counsel | A | A | 254,780.0 | 0.0 | 0.0 | 254,780.0 | View | |
| Jul 08, 2026 | Chief Executive Officer | A | A | 3,000,000.0 | 0.0 | 0.0 | 3,000,000.0 | View | |
| Jul 07, 2026 | SVP, Clinical Development | M | D | 5,405.0 | 0.0 | 0.0 | 0.0 | View | |
| Jul 07, 2026 | SVP, Clinical Development | S | D | 4,485.0 | 0.89 | 3,991.65 | 298,101.0 | View | |
| Jul 07, 2026 | SVP, Clinical Development | M | A | 12,432.0 | — | — | 302,586.0 | View | |
| Jun 30, 2026 | — | A | A | 1,010,100.0 | 0.0 | 0.0 | 1,010,100.0 | View | |
| Jun 30, 2026 | — | A | A | 1,087,720.0 | 0.0 | 0.0 | 1,087,720.0 | View | |
| Jun 30, 2026 | — | A | A | 1,087,720.0 | 0.0 | 0.0 | 1,087,720.0 | View | |
| Jun 30, 2026 | — | A | A | 725,140.0 | 0.0 | 0.0 | 725,140.0 | View | |
| Jun 24, 2026 | Chief Bus. Development Officer | A | A | 181,290.0 | 0.0 | 0.0 | 181,290.0 | View | |
| Jun 24, 2026 | Chief Bus. Development Officer | A | A | 181,280.0 | 0.0 | 0.0 | 181,280.0 | View | |
| Jun 22, 2026 | Chief Medical Officer | M | D | 10,302.0 | 0.0 | 0.0 | 82,422.0 | View | |
| Jun 22, 2026 | Chief Medical Officer | S | D | 8,494.0 | 0.66 | 5,606.04 | 157,941.0 | View | |
| Jun 22, 2026 | Chief Medical Officer | M | A | 23,695.0 | — | — | 166,435.0 | View | |
| Jun 02, 2026 | SVP, Clinical Development | M | D | 4,079.0 | 0.0 | 0.0 | 32,637.0 | View | |
| Jun 02, 2026 | SVP, Clinical Development | S | D | 3,494.0 | 3.94 | 13,766.36 | 290,154.0 | View | |
| Jun 02, 2026 | SVP, Clinical Development | M | A | 9,382.0 | — | — | 293,648.0 | View | |
| May 18, 2026 | See Remarks | S | D | 21,399.0 | 1.99 | 42,584.01 | 35,073.0 | View | |
| Apr 28, 2026 | See Remarks | P | A | 230,000.0 | 2.51 | 577,300.0 | 230,000.0 | View |